Targeted therapy for metastatic renal cell carcinoma

Br J Cancer. 2006 Mar 13;94(5):614-9. doi: 10.1038/sj.bjc.6602978.

Abstract

Metastatic renal cell carcinoma (RCC) has historically been refractory to cytotoxic and hormonal agents; only interleukin 2 and interferon alpha provide response in a minority of patients. We reviewed RCC biology and explored the ways in which this understanding led to development of novel, effective targeted therapies. Small molecule tyrosine kinase inhibitors, monoclonal antibodies and novel agents are all being studied, and phase II studies show promising activity of sunitinib, sorafenib and bevacizumab. The results of phase III studies will determine the role of these agents in metastatic RCC.

Publication types

  • Review

MeSH terms

  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Benzenesulfonates / therapeutic use
  • Bevacizumab
  • Carcinoma, Renal Cell / drug therapy*
  • Carcinoma, Renal Cell / secondary
  • Clinical Trials as Topic
  • Enzyme Inhibitors / therapeutic use*
  • Humans
  • Indoles / therapeutic use
  • Kidney Neoplasms / drug therapy*
  • Kidney Neoplasms / pathology
  • Neoplasm Metastasis
  • Niacinamide / analogs & derivatives
  • Phenylurea Compounds
  • Protein-Tyrosine Kinases / antagonists & inhibitors*
  • Pyridines / therapeutic use
  • Pyrroles / therapeutic use
  • Sorafenib
  • Sunitinib

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Benzenesulfonates
  • Enzyme Inhibitors
  • Indoles
  • Phenylurea Compounds
  • Pyridines
  • Pyrroles
  • Niacinamide
  • Bevacizumab
  • Sorafenib
  • Protein-Tyrosine Kinases
  • Sunitinib